The estimated Net Worth of Frank E Thomas is at least 3.51 百万$ dollars as of 10 March 2023. Mr Thomas owns over 20,000 units of Orchard Therapeutics plc stock worth over 1,537,753$ and over the last 20 years he sold ORTX stock worth over 1,389,400$. In addition, he makes 586,181$ as Pres & COO at Orchard Therapeutics plc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr Thomas ORTX stock SEC Form 4 insiders trading
Mr has made over 15 trades of the Orchard Therapeutics plc stock since 2005, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of ORTX stock worth 9,200$ on 10 March 2023.
The largest trade he's ever made was exercising 20,000 units of Orchard Therapeutics plc stock on 10 March 2023 worth over 9,200$. On average, Mr trades about 1,785 units every 102 days since 2004. As of 10 March 2023 he still owns at least 92,081 units of Orchard Therapeutics plc stock.
You can see the complete history of Mr Thomas stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Frank E. Thomas biography
Frank E. Thomas is the Pres & COO at Orchard Therapeutics plc.
What is the salary of Mr Thomas?
As the Pres & COO of Orchard Therapeutics plc, the total compensation of Mr Thomas at Orchard Therapeutics plc is 586,181$. There are 1 executives at Orchard Therapeutics plc getting paid more, with Dr. Bobby Gaspar Ph.D., M.D. having the highest compensation of 712,410$.
How old is Mr Thomas?
Mr Thomas is 51, he's been the Pres & COO of Orchard Therapeutics plc since . There are 1 older and no younger executives at Orchard Therapeutics plc. The oldest executive at Orchard Therapeutics plc is Dr. Bobby Gaspar Ph.D., M.D., 56, who is the CEO, Member of Scientific Advisory Board & Exec. Director.
What's Mr Thomas's mailing address?
Frank's mailing address filed with the SEC is C/O SPERO THERAPEUTICS, INC., 675 MASSACHUSETTS AVENUE, 14TH FLOOR, CAMBRIDGE, MA, 02139.
Insiders trading at Orchard Therapeutics plc
Over the last 5 years, insiders at Orchard Therapeutics plc have traded over 14,660,920$ worth of Orchard Therapeutics plc stock and bought 794,017 units worth 3,579,149$ . The most active insiders traders include Capital Management, L.P.Ra ...、Llc Fmr、Charles A Jr Rowland. On average, Orchard Therapeutics plc executives and independent directors trade stock every 116 days with the average trade being worth of 4,897,976$. The most recent stock trade was executed by Frank E Thomas on 10 March 2023, trading 20,000 units of ORTX stock currently worth 9,200$.
What does Orchard Therapeutics plc do?
orchard therapeutics is dedicated to bringing transformative gene therapies to children with life-threatening orphan diseases. we work in partnership with the world’s most prestigious research centres to harness the life-giving potential of gene therapy. orchard’s leadership team and collaborators have more than a decade of experience in the development, manufacturing and commercialization of advanced therapies for orphan diseases. our mission is to provide the ideal environment and expertise to translate promising pre-clinical and early clinical results into commercially approved medicines available to patients around the world.
What does Orchard Therapeutics plc's logo look like?
Complete history of Mr Thomas stock trades at AMAG Pharmaceuticals、Zafgen、Spero Therapeutics Inc、Orchard Therapeutics plc、Cortexyme Inc
Orchard Therapeutics plc executives and stock owners
Orchard Therapeutics plc executives and other stock owners filed with the SEC include:
-
Dr. Bobby Gaspar Ph.D., M.D.,
CEO, Member of Scientific Advisory Board & Exec. Director -
Frank E. Thomas,
Pres & COO -
Braden Parker,
Chief Commercial Officer -
Robin Kenselaar,
Sr. VP & GM of EMEA Commercial Operations -
Dr. Anne Dupraz-Poiseau,
Chief Devel. Officer -
John Cerio,
Chief Human Resource Officer -
Benjamin Navon,
Director of Corp. Communications -
Renee T. Leck,
Director of Investor Relations -
Dr. Fulvio Mavilio Ph.D.,
Chief Scientific Officer -
Dr. Nicoletta Loggia Ph.D.,
Chief Technical Officer -
Alicia Secor,
-
Steven Altschuler,
-
Marc Dunoyer,
-
James A Geraghty,
-
Llc Fmr,
-
Charles A Jr Rowland,
-
Capital Management, L.P.Ra ...,
-
Joanne T. Beck,
-
John T Curnutte,
-
Bobby Gaspar,
Chief Executive Officer -
Frank E Thomas,
See Remarks